Literature DB >> 4153646

The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study.

P Anthonisen, F Barany, O Folkenborg, A Holtz, S Jarnum, M Kristensen, P Riis, A Walan, H Worning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4153646

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN： 0036-5521            Impact factor:   2.423


× No keyword cloud information.
  18 in total

1.  Frontiers in inflammatory bowel disease. The proceedings of a conference sponsored by the McReynolds Foundation. Part II.

Authors:  R G Shorter; D A Shephard
Journal:  Am J Dig Dis       Date:  1975-07

2.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

3.  Medical management of Crohn's disease.

Authors:  Paul A Feldman; Daniel Wolfson; Jamie S Barkin
Journal:  Clin Colon Rectal Surg       Date:  2007-11

Review 4.  Ulcerative colitis and Crohn's colitis: differential diagnosis and treatment.

Authors:  T C Northfield
Journal:  Drugs       Date:  1977-09       Impact factor: 9.546

Review 5.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

6.  Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.

Authors:  P A Van Hees; H J Van Lier; P H Van Elteren; M Driessen; R A Van Hogezand; G P Ten Velde; J H Bakker; J H Van Tongeren
Journal:  Gut       Date:  1981-05       Impact factor: 23.059

7.  Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.

Authors:  H Mielants; E M Veys; R Joos
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

8.  Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan.

Authors:  Fumiaki Ueno; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Matsuoka; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2012-10-23       Impact factor: 7.527

Review 9.  Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes.

Authors:  R L Parsons
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

10.  Home elemental enteral hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease.

Authors:  H Hirakawa; Y Fukuda; N Tanida; M Hosomi; T Shimoyama
Journal:  Gastroenterol Jpn       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.